Ono Pharmaceutical Co., Ltd. (TYO:4528)
Japan · Delayed Price · Currency is JPY | Market Cap | 1.04T |
| Revenue (ttm) | 503.67B |
| Net Income (ttm) | 48.50B |
| Shares Out | 469.91M |
| EPS (ttm) | 103.10 |
| PE Ratio | 21.37 |
| Forward PE | 14.84 |
| Dividend | 80.00 (3.67%) |
| Ex-Dividend Date | Mar 30, 2026 |
| Volume | 880,500 |
| Average Volume | 2,082,730 |
| Open | 2,220.00 |
| Previous Close | 2,203.00 |
| Day's Range | 2,206.00 - 2,229.00 |
| 52-Week Range | 1,474.00 - 2,237.00 |
| Beta | -0.02 |
| RSI | 67.73 |
| Earnings Date | Feb 2, 2026 |
About Ono Pharmaceutical
Ono Pharmaceutical Co., Ltd. produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo intravenous infusion and Kyprolis intravenous injection for malignant tumors; Emend capsule intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; Mektovi, Velexbru, and Braftovi capsules for malignant tumors; and ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabet... [Read more]
Financial Performance
In 2024, Ono Pharmaceutical's revenue was 486.87 billion, a decrease of -3.14% compared to the previous year's 502.67 billion. Earnings were 50.05 billion, a decrease of -60.89%.
Financial StatementsNews
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting
OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announc...
Deciphera Announces the Opening of a New Office in Zug, Switzerland
OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the opening of a new 733-square-mete...
Deciphera Announces Multiple Data Presentations at the Connective Tissue Oncology Society (CTOS) Annual Meeting 2025
OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced that data from multiple pipeline pro...
Ono Pharmaceutical reports Q2 results
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 2025
OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety res...
Ono Announces Encouraging Efficacy Signals of ONO-2808, a S1P5 Receptor Agonist, in an interim analysis of Ongoing Phase 2 Clinical Trial in Patients with Multiple System Atrophy
Efficacy signals were observed in an interim analysis of a Phase 2 clinical trial for ONO-2808, a S1P5 receptor agonist Phase 2 clinical trial was conducted in early multiple system atrophy patients w...
Deciphera Receives European Commission Approval of ROMVIMZA™ (vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)
OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced that the European Commission (EC) ha...
Ono Pharmaceutical Co., Ltd. 2025 Q1 - Results - Earnings Call Presentation
Ono Pharmaceutical Co., Ltd. (OPHLF) Q1 FY2025 Earnings Call Transcript
Deciphera Announces Positive CHMP Opinion for ROMVIMZA™ (vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)
OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, LLC, a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines, and Ono Pha...
Vertex and Ono Pharmaceutical form exclusive alliance for Povetacicept in Japan and South Korea
Ono Pharmaceutical and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea
Ono and Vertex have entered into an exclusive collaboration and license agreement for povetacicept in Japan and South Korea Povetacicept is a therapeutic in development for multiple serious B cell-med...
Ono Pharmaceutical and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea
OSAKA, Japan & BOSTON--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”) and Vertex Pharmaceuticals Incorporated (Headquarters: Boston...
Ono Pharmaceutical Co., Ltd. 2025 Q4 - Results - Earnings Call Presentation
Ono Pharmaceutical reports FY results
What's Going On With Cue Biopharma Shares Tuesday?
Cue Biopharma, Inc. (NASDAQ: CUE) shares are trading lower on Tuesday. The company reported 2024 fiscal-year earnings on Monday after the market closed. What To Know: The company reported collaborati...
Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal
On Tuesday, Ionis Pharmaceuticals Inc (NASDAQ: IONS) and Ono Pharmaceutical Co., Ltd entered into a license agreement in which Ono obtains exclusive global rights for the development and commercializ...
Ionis out licenses blood disorder therapy to Ono in a deal worth up to $940M
Ionis Pharmaceuticals (NASDAQ:IONS) stock in focus as the company inks a $940M deal with Ono Pharmaceutical (OPHLY) to license a blood disorder drug. Read more here.
U.S. FDA Grants Full Approval of Deciphera's ROMVIMZA™ (vimseltinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor (TGCT)
In the MOTION Phase 3 study, ROMVIMZA met primary endpoint of improved objective response rate (ORR) compared to placebo and all key secondary endpoints with statistically significant and clinically m...
U.S. FDA Grants Full Approval of Deciphera's ROMVIMZA™ (vimseltinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor (TGCT)
OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; “Ono”) announced that the U.S. Food and Drug Administration (FDA) ha...
Ono Pharmaceutical GAAP EPS of ¥162.87, revenue of ¥374.56B; reaffirms FY outlolok
Ono Pharmaceutical reports Q2 results
Equillium says Ono not acquiring itolizumab, stock craters 36%
Equillium (EQ) stock cratered 36% after the company said it was pausing certain programs due to Ono Pharmaceutical failing to exercise an option to acquire its drug itolizumab.
Kinaxis to Bolster Supply Chain Operations of Ono Pharmaceutical
Kinaxis provides end-to-end supply chain orchestration platform to support Ono Pharmaceutical’s further global growth OTTAWA, Ontario — Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply ch...
Kinaxis to Bolster Supply Chain Operations of Ono Pharmaceutical
OTTAWA, Ontario--(BUSINESS WIRE)--Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced Ono Pharmaceutical Co., Ltd.'s adoption of Kinaxis to help orchestr...